Healthcare Distribution Alliance Defends Law Weakening DEA. A Law It Helped Finance. | Pharmaguy's Insights Into Drug Industry News |

A major trade association for pharmaceutical distributors defended a law that weakened the Drug Enforcement Administration (DEA), while ignoring key facts about how the now-stripped power once let the agency suspend distributors that shipped alarming numbers of opioid pills.


The pharmaceutical industry – including the Healthcare Distribution Alliance – spent millions lobbying for the Ensuring Patient Access and Effective Drug Enforcement Act, which made it nearly impossible for the DEA to suspend drug distributors if their opioid-based painkiller shipments reached suspicious volumes, The Washington Post and 60 Minutes jointly reported (read “How Congress Allied with Drug Company Lobbyists to Derail the DEA’s War on Opioids”;


The alliance called the DEA’s suspensions a “hit-and-miss approach” that jeopardized legitimate patients’ access to opioid-based painkillers.


The alliance has also argued that, prior to the new law, the DEA didn’t set clear guidance on how large pill shipments would be considered suspicious, and that the agency didn’t communicate well enough with distributors.


But the Healthcare Distribution Alliance ignored examples in the WaPo/60 Minutes report where the DEA suspended distributors that were shipping especially large numbers of pills.


In one instance, 11 million painkillers were shipped to a West Virginia county with a population of 25,000, according to the WaPo/60 Minutes investigation. In another, some Walgreens pharmacies in Florida sold more than one million opioid pills a year – nearly 14 times the number sold by a typical pharmacy.


The trade association also said the primary source for the WaPo/60 Minutes investigation was a former DEA official who consults trial lawyers suing the pharmaceutical industry. But the article included interviews with other several other sources and quotes from a significant number of documents.


The DEA’s aggressiveness with suspensions was already hampered before the law passed, according to the WaPo/60 Minutes investigation. Officials were forced to present more evidence before suspending distributors and the agency’s management became more willing to cooperate with the pharmaceutical industry.


Meanwhile, dozens of DEA officials left the agency and took jobs with drug companies over the past few years, according to the investigation.


Additionally, the Healthcare Distribution Alliance spent $3.5 million on lobbying in support of the legislation between 2014 and 2016, WaPo/60 Minutes found, which the association didn’t address in its statement.